Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Lung Neoplasms 5Adenocarcinoma of Lung 5Neoplasms 3Lymphoma, Large-Cell, Anaplastic 3Granuloma, Plasma Cell 3Hematologic Neoplasms 2Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) 1Rhabdomyosarcoma 1Neuroblastoma 1Lymphoma, B-Cell 1Glioblastoma 1Cholangiocarcinoma 1Brain Neoplasms 1Adenocarcinoma Of Esophagus 1ALK-positive NSCLC 1ALK-positive Advanced Tumors 1

Interventions

Crizotinib 2lorlatinib 1ceritinib 1brigatinib 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × ALK-positive NSCLC × ceritinib × Clear all
NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

Completed
549 enrolled 28 charts
Thoracic

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡